Kamada (KMDA) Projected to Post Quarterly Earnings on Wednesday

Kamada (NASDAQ:KMDA) is expected to release its Q4 2025 results before the market opens on Wednesday, March 4th. Analysts expect the company to announce earnings of $0.09 per share and revenue of $145.0670 million for the quarter. Individuals can check the company’s upcoming Q4 2025 earning summary page for the latest details on the call scheduled for Wednesday, March 11, 2026 at 8:00 AM ET.

Kamada Stock Performance

KMDA stock opened at $9.07 on Tuesday. Kamada has a one year low of $5.54 and a one year high of $9.35. The firm has a market cap of $521.62 million, a price-to-earnings ratio of 25.20, a PEG ratio of 0.74 and a beta of 0.94. The firm has a 50-day simple moving average of $8.12 and a two-hundred day simple moving average of $7.35.

Wall Street Analyst Weigh In

A number of equities research analysts recently commented on KMDA shares. Wall Street Zen raised shares of Kamada from a “buy” rating to a “strong-buy” rating in a research report on Saturday, December 13th. Weiss Ratings reaffirmed a “buy (b-)” rating on shares of Kamada in a research report on Thursday, January 22nd. HC Wainwright raised their price objective on Kamada from $11.00 to $13.00 and gave the stock a “buy” rating in a research report on Tuesday, December 9th. Finally, Benchmark restated a “buy” rating on shares of Kamada in a research note on Thursday, January 8th. Three research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $14.00.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the business. Jane Street Group LLC acquired a new position in shares of Kamada during the 1st quarter worth about $582,000. Goldman Sachs Group Inc. purchased a new position in shares of Kamada in the first quarter valued at approximately $497,000. Arrowstreet Capital Limited Partnership purchased a new position in shares of Kamada in the second quarter valued at approximately $472,000. Bank of America Corp DE boosted its stake in shares of Kamada by 201.0% in the third quarter. Bank of America Corp DE now owns 61,565 shares of the biotechnology company’s stock worth $427,000 after acquiring an additional 41,111 shares during the last quarter. Finally, Marshall Wace LLP increased its position in shares of Kamada by 25.9% during the fourth quarter. Marshall Wace LLP now owns 196,954 shares of the biotechnology company’s stock worth $1,390,000 after purchasing an additional 40,514 shares in the last quarter. 20.38% of the stock is owned by institutional investors and hedge funds.

Kamada Company Profile

Kamada Ltd. is a biopharmaceutical company headquartered in Israel that specializes in the development, manufacturing and commercialization of plasma‐derived protein therapeutics. The company focuses on treatments for rare and serious diseases, leveraging its proprietary fractionation and purification technologies to produce purified human proteins. Kamada’s product portfolio addresses critical therapeutic areas in immunology, hematology and pulmonology, where alternative treatment options may be limited.

Among Kamada’s marketed products is Glassia®, an alpha‐1 antitrypsin augmentation therapy approved by the U.S.